Methods for treating edema by administering a Soluble Hyaluronidase Glycoprotein (sHASEGP)

Patent Citations (146)

Non-Patent Literature (508)

• Letter/Written Disclosure of the Information Disclosure Statement for the above-referenced application, mailed on Jul. 12, 2012, 3 pages.Applicant
• Adams et al., “The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice,” Nature 318:533-538 (1985).Applicant
• Afify et al., “Purification and characterization of human serum hyaluronidases,” Arch. Biochem. Biophys. 305:434-441 (1993).Applicant
• Alberts, B., Molecular Biology of the Cell, Garland Publishing Inc. New York and London, 3rd ed., p. 347 (1983).Applicant
• Alexander et al., “Expression of the c-myc oncogene under control of an immunoglobulin enhancer in E mu-myc transgenic mice,” Mol. Cell Biol. 7:1436-1444 (1987).Applicant
• Altschul, S., “Basic local alignment search tool,” J Molec Biol 215(3):403-410 (1990).Applicant
• Antoszyk et al., “An experimental model of preretinal neovascularization in the rabbit,” Invest Ophthalmol Vis Sci 32(1):46-51 (1991).Applicant
• Arming et al., “In vitro mutagenesis of PH-20 hyaluronidase from human sperm,” Eur J Biochem 247(3):810-814 (1997).Applicant
• Ashwell, G. and J. Harford, “Carbohydrate-specific receptors of the liver,” Ann. Rev. Biochem. 51:531-554 (1982).Applicant
• Bailey, L. and N. Levine, “Optimization of the USP assay for hyaluronidase,” Journal of Pharmaceutical & Biomedical Analysis 11(4/5):285-292 (1993).Applicant
• Baumgartner et al., “Phase I study in chemoresistant loco-regional malignant disease with hyaluronidase,” Reg. Cancer Treat. 1:55-58 (1988).Applicant
• Beckenlehner et al., “Hyaluronidase enhances the activity of adriamycin in breast cancer models in vitro and in vivo,” J. Cancer Res. Oncol. 118:591-596 (1992).Applicant
• Benton, W. and R. Davis, “Screening lambdagt recombinant clones by hybridization to single plaques in situ,” Science 196:180-182 (1977).Applicant
• Berger E., “Nutrition by hypodermoclysis,” Am Geriatr Soc 32(3):199-203 (1984).Applicant
• Bernoist, C. and P. Chambon, “In vivo sequence requirements of the SV40 early promotor region,” Nature 290:304-310 (1981).Applicant
• Bernstein et al., “Role for a bidentate ribonuclease in the initiation step of RNA interference,” Nature 409:363-366 (2001).Applicant
• Bertrand et al., “Hyaluronan (hyaluronic acid) and hyaluronectin in the extracellular matrix of human breast carcinomas: comparison between invasive and non-invasive areas,” Int. J. Cancer 52:1-6 (1992).Applicant
• Bianchi et al., “Synthetic depsipeptide substrates for the assay of human hepatitis C virus protease,” Anal. Biochem. 237: 239-244 (1996).Applicant
• Bitter et al., “Expression and secretion vectors for yeast,” Methods in Enzymol 153:516-544 (1987).Applicant
• Bjermer et al., “Hyaluronate and type III procollagen peptide concentrations in bronchoalveolar lavage fluid as markers of disease activity in farmer's lung,” Br Med J Clin Res Ed. 295(6602):803-806 (1987).Applicant
• Boesen et al., “Circumvention of chemotherapy-induced myelosuppression by transfer of the mdr1 gene,” Biotherapy 6:291-302 (1994).Applicant
• Bonner, W. and E. Cantey, “Colorimetric method for determination of serum hyaluronidase activity,” Clin. Chim. Acta 13:746-752 (1966).Applicant
• Bookbinder et al., “A Recombinant Human Enzyme for Enhanced Interstitial Transport of Therapeutics,” J Control Release, 114:230-24 (2006).Applicant
• Borders, C. and M. Rafferty, “Purification and partial characterization of testicular hyaluronidase,” J. Biol. Chem 13:3756-3762 (1968).Applicant
• Bordier C., “Phase separation of integral membrane proteins in Triton X-114 solution,” J Biol Chem. 256(4):1604-1607 (1981).Applicant
• Bouffard et al., “An in vitro assay for hepatitis C virus NS3 serine proteinase,” Virology 209:52-59 (1995).Applicant
• Bout et al., “Lung gene therapy: in vivo adenovirus-mediated gene transfer to rhesus monkey airway epithelium,” Human Gene Therapy 5:3-10 (1994).Applicant
• Bradbury et al., “Chondroitinase ABC promotes functional recovery after spinal cord injury,” Nature 416(6881):636-640 (2002).Applicant
• Brinster et al., “Regulation of metallothionein—thymidine kinase fusion plasmids injected into mouse eggs,” Nature 296:39-42 (1982).Applicant
• Brown et al., “Cluster of diplopia cases after periocular anesthesia without hyaluronidase,” J Cataract Refract Surg. 25(9):1245-1249 (1999).Applicant
• Callewaert et al., “Ultrasensitive profiling and sequencing of N-linked oligosaccharides using standard DNA-sequencing equipment,” Glycobiology 11:275-281 (2001).Applicant
• Capecchi, M., “Altering the genome by homologous recombination,” Science 244:1288-1292 (1989).Applicant
• Carrillo, H. and D. Lipman, “The multiple-sequence alignment problem in biology,” SIAM J Applied Math 48(5):1073-1082 (1988).Applicant
• Chain, E. and E. Duthie, “A mucolytic enzyme in testis extracts,” Nature 144:977-978 (1939).Applicant
• Chain, E. and E. Duthie, “Identity of hyaluronidase and spreading factor,” Brit. J. Exper. Path. 21:324-338 (1940).Applicant
• Cherr et al., “The dual functions of GP1-anchored PH-20: hyaluronidase and intracellular signaling,” Matrix Biol., 20(8):515-525 (2001).Applicant
• Cherr et al., “The PH-20 protein in cynomolgus macaque spermatozoa: identification of two different forms exhibiting hyaluronidase activity,” Dev. Biol., 175:142-153 (1996).Applicant
• Cho et al., “Construction of hepatitis C-SIN virus recombinants with replicative dependency on hepatitis C virus serine protease activity,” J. Virol. Meth. (65):201-207 (1997).Applicant
• Chuang, C. and E. Meyerowitz, “Specific and heritable genetic interference by double-stranded RNA in Arabidopsis thaliana,” Proc. Natl. Acad. Sci. USA 97:4985-4990 (2000).Applicant
• Cline, M., “Perspectives for gene therapy: inserting new genetic information into mammalian cells by physical techniques and viral vectors,” Pharmac. Ther. 29:69-92 (1985).Applicant
• Clowes et al., “Long-term biological response of injured rat carotid artery seeded with smooth muscle cells expressing retrovirally introduced human genes,” J. Clin. Invest. 93:644-651 (1994).Applicant
• Colbere-Garapin et al., “A new dominant hybrid selective marker for higher eukaryotic cells,” J Mol Biol 150:1-14 (1981).Applicant
• Cole, G. and C. McCabe, “Identification of a developmentally regulated keratan sulfate proteoglycan that inhibits cell adhesion and neurite outgrowth,” Neuron 7(6):1007-1018 (1991).Applicant
• Conserved domain search from U.S. Appl. No. 10/795,095 of SEQ ID No. 6, Primakoff et al. US 5,721,348, performed on the NCBI website on Aug. 5, 2008, 1 page.Applicant
• Cotten et al., “Receptor-mediated transport of DNA into eukaryotic cells,” Meth. Enzymol. 217:618-644 (1993).Applicant
• Csoka et al., “Hyaluronidases in tissue invasion,” Invasion Metastasis 17:297-311 (1997).Applicant
• Csoka et al., “Purification and microsequencing of hyaluronidase isozymes from human urine,” FEBS Lett., 417(3):307-310 (1997).Applicant
• Csoka et al., “The six hyaluronidase-like genes in the human and mouse genomes,” Matrix Biol. 20:499-508 (2001).Applicant
• Cummings, R., “Use of lectins in analysis of glycoconjugates,” Methods in Enzymol. 230:66-86 (1994).Applicant
• Czejka et al., “Influence of hyaluronidase on the blood plasma levels of 5-fluorouracil in patients,” Pharmazie 45:H.9 (1990).Applicant
• Danilkovitch-Miagkova, et al., “Hyaluronidase 2 negatively regulates RON receptor tyrosine kinase and mediates transformation of epithelial cells by jaagsiekte sheep retrovirus,” Proc Natl Acad Sci US A. 100(8):4580-4585 (2003).Applicant
• De Maeyer et al., “The growth rate of two transplantable murine tumors, 3LL lung carcinoma and B16F10 melanoma, is influenced by Hyal-1, a locus determining hyaluronidase levels and polymorphism,” Int. J. Cancer 51:657-660 (1992).Applicant
• De Sa Earp, “Hemiplegia secondary to cerebromeningeal hemorrhage treated with hyaluronidase with complete recovery ,” Arq. Braz. Med. 44:217-220 (1954). [Certified English language translation].Applicant
• De Salegui et al., “A Comparison of Serum and Testicular Hyaluronidase,” Arch. Biochem. Biophys. 121:548-554 (1967).Applicant
• DeBoer et al., “The tac promoter: a functional hybrid derived from the trp and lac promoters,” Proc. Natl. Acad. Sci. USA 80:21-25 (1983).Applicant
• Derwent Abstract. Acc No. 1988-105412/198815 for WO 1988/002261. Inventor: Baumgartner et al. Abstract published 1988. 2 pages.Applicant
• Devereux et al, “A comprehensive set of sequence analysis programs for the VAX,” Nucleic Acids Research 12:387-395 (1984).Applicant
• Dexter et al., “Conditions controlling the proliferation of haemopoietic stem cells in vitro,” J. Cell Physiol. 91(3):335-344 (1977).Applicant
• Dillon, N., “Regulating gene expression in gene therapy,” TIBTECH 11(5):167-173 (1993).Applicant
• Dodet, B., “Commercial prospects for gene therapy,” TIBTECH 11(5):182-189 (1993).Applicant
• Dorfman, A. and M. Ott, “A turbidimetric method for the assay of hyaluronidase,” J. Biol. Chem. 172:367-375 (1948).Applicant
• Dorfman, A., “The kinetics of the enzymatic hydrolysis of hyaluronic acid,” J. Biol. Chem. 172:377-387 (1948).Applicant
• Drug Shortage Bulletin, “Hyaluronidase Injection—Discontinued,” Published on Jan. 18, 2005 [online][retrieved on Mar. 21, 2006] Retrieved from:<URL:ashp.org/shortage/hyaluronidase.cfm?cfid=11944667&CFToken=9426953%2 [1 page].Applicant
• Drugs R&D, “Hyaluronidase (Vitrase®)—ISTA,” 4(3):194-197 (2003).Applicant
• D'Souza et al., “In vitro cleavage of hepatitis C virus polyprotein substrates by purified recombinant NS3 protease,” J. Gen. Virol. 76:1729-1736 (1995).Applicant
• Dubensky et al., “Direct transfection of viral and plasmid DNA into the liver or spleen of mice,” Proc Natl Acad Sci U S A 81(23):7529-7533 (1984).Applicant
• Dunn et al., “Transcription of the human and rodent SPAM1/PH-20 genes initiates within an ancient endogenous retrovirus,” BMC Genomics, 6:47 (2005).Applicant
• Duran-Reynals, F., “Exaltation de l'Activite du Virus Vaccinal par les Extraits de Certains Organes,” Comptes Rendus Hebdomadaires de Seances et Memoires de la Societe de Biologie 99: 6-7 (1928) [Certified English Translation].Applicant
• Dzau et al., “Gene therapy for a cardiovascular disease,” TIBTECH 11(5):205-210 (1993).Applicant
• Edelson, E., “Wydase shortage creates alert; task force seeks new source,” Opthamology Times, Jan. 1, 2001.Applicant
• Elbashir et al., “Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells,” Nature 41(1):494-498 (2001).Applicant
• Elbashir et al., “RNA interference is mediated by 21- and 22-nucleotide RNAs,” Genes Dev. 15:188-200 (2001).Applicant
• Elder et. al, “Intra-arterial hyaluronidase in severe peripheral arterial disease,” Lancet 648-649 (1980).Applicant
• European Medicines Agency (EMEA) guideline 3AB1a, “Production and quality control of medicinal products derived by recombinant DNA technology,” pp. 205-216, published Jul. 1995.Applicant
• European Medicines Agency (EMEA) guideline CPMP/BWP/268/95 3AB8a, “Virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses,” pp. 1-13 published, Feb. 1996.Applicant
• European Medicines Agency (EMEA) guideline CPMP/ICH/295/95 ICH Topic 5QA (R1), “Quality of biotechnological products: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin,” pp. 1-29 published Mar. 1997.Applicant
• European Medicines Agency (EMEA) guideline CPMP/ICH/365/96 ICH Topic Q6B, “Specifications: test procedures and acceptance criteria for biotechnical/biological products,” pp. 1-17 published, Mar. 1999.Applicant
• Favre et al, “Hyaluronidase enhances recombinant adeno-associated virus (rAAV)-mediated gene transfer in the rat skeletal muscle,” Gene Ther 7(16):1417-1420 (2000).Applicant
• Federal Register Sep. 23, 1970 (35 FR 14800); Wydase NDA 6-343, 40 pages.Applicant
• Few, B., “Hyaluronidase for treating intravenous extravasations,” MCN Amer. J. Matern. Child Nurs. 12(1):23-26 (1987).Applicant
• Filocamo et al., “Chimeric Sindbis viruses dependent on the NS3 protease of hepatitis C virus,” J.Virology 71:1417-1427 (1997).Applicant
• Findeis et al., “Targeted delivery of DNA for gene therapy via receptors,” TIBTECH 11(5):202-205 (1993).Applicant
• Fire et al., “Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans,” Nature (39)1:806-811 (1998).Applicant
• Fire, A., “RNA-triggered gene silencing,” Trends Genet. 15:358-363 (1999).Applicant
• Fletcher et al., “Antinociceptive effect of bupivacaine encapsulated in poly(D,L)-lactide-co-glycolide microspheres in the acute inflammatory pain model of carrageenin-injected rats,” Anesth. Analg. 84:90-94 (1997).Applicant
• Form 10-Q for Halozyme Therapeutics [online], Published on May 8, 2009 [retrieved on Nov. 25, 2009] [retrieved from the Internet:<URL:biz.yahoo.com/e/090508/halo10-q.html] [6 pages].Applicant
• Friedmann, T. and H. Jinnah, “Gene therapy for disorders of the nervous system,” TIBTECH 11(5):192-197 (1993).Applicant
• Friedmann, T., “Gene therapy—a new kind of medicine,” TIBTECH 11(5) 156-159 (1993).Applicant
• Frost et al., “Purification, cloning, and expression of human plasma hyaluronidase,” Biochem. Biophys. Res. Commun. 236:10-15 (1997).Applicant
• Frost, G. and R. Stern, “A microtiter-based assay for hyaluronidase activity not requiring specialized reagents,” Anal. Biochem. 251:263-269 (1997).Applicant
• Frost, G., “Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration,” Expert Opin. Drug. Deliv. 4:427-440 (2007).Applicant
• Gacesa et al., “Effect of ionic strength and serum on the activity profile of bovine testicular hyaluronidase [proceedings],” Biochem. Soc. Trans. 7:1287-1289 (1979).Applicant
• Gardner et al., “The complete nucleotide sequence of an infectious clone of cauliflower mosaic virus by M13mp7 shotgun sequencing,” Nucleic Acids Res. 9:2871-2888 (1981).Applicant
• Gautier et al., “Alpha-DNA. IV: Alpha-anomeric and beta-anomeric tetrathymidylates covalently linked to intercalating oxazolopyridocarbazole. Synthesis, physicochemical properties and poly (rA) binding,” Nucl. Acids Res. 15:6625-6641 (1987).Applicant
• Geisert, E. and D. Bidanset, “A central nervous system keratan sulfate proteoglycan: localization to boundaries in the neonatal rat brain,” Brain Res Dev Brain Res. 75(2):163-173 (1993).Applicant
• Genbank Accession No. L13780 [online], Macaca fascicularis sperm surface protein PH-20 mRNA sequence, Published on Jan. 31, 1994 [retrieved on Apr. 29, 2011] [retrieved from the Internet:<URL: ncbi.nlm.nih.gov/nuccore/L13780], 1 page.Applicant
• Genbank Accession No. P38567 [online], “RecName: Full=Hyaluronidase PH-20; Short=Hyal-PH20; AltName: Full=Hyaluronoglucosaminidase PH-20; AltName: Full=Sperm adhesion molecule 1; AltName: Full=Sperm surface protein PH-20; Flags: Precursor,” [retrieved on Apr. 18, 2011] [retrieved from the Internet:<URL:ncbi.nlm.nih.gov/protein/P38567.1], 8 pages.Applicant
• Genbank Accession No. P48794 [online], RecName: Full=Hyaluronidase PH-20; Short=Hyal-PH20; AltName: Full=Hyaluronoglucosaminidase PH-20; AltName: Full=Sperm adhesion molecule 1; AltName: Full=Sperm surface protein PH-20; Flags: Precursor, Published on Mar. 8, 2011 [retrieved on Apr. 29, 2011] [retrieved from the Internet:<URL:ncbi.nlm.nih.gov/protein/P48794], 4 pages.Applicant
• Genbank Accession No. NP-003108, “Homo sapiens sperm adhesion molecule 1 Isoform 1,” Published on Feb. 10, 2008 [online][retrieved on May 1, 2008] [retrieved from the Internet:<URL:ncbi.nlm.nih.gov/protein/21314606], 5 pages.Applicant
• Gerber et al., “Phosphatidylinositol Glycan (PI-G) Anchored Membrane Proteins” J. Biol. Chem. 267(17):12168-12178 (1992).Applicant
• Gilbert, W. and L. Villa-Komaroff, “Useful proteins from recombinant bacteria,” Scientific American 242(4):74-94 (1980).Applicant
• Gmachl et al., “The human sperm protein PH-20 has hyaluronidase activity,” FEBS 336(3):545-548 (1993).Applicant
• Gold, E., “Purification and properties of hyaluronidase from human liver. Differences from and similarities to the testicular enzyme,” Biochem. J. 205:69-74 (1982).Applicant
• Goldspiel et al., “Human gene therapy,” Clinical Pharmacy 12:488-505 (1993).Applicant
• Goochee et al., “The oligosaccharides of glycoproteins: bioprocess factors affecting oligosaccharide structure and their effect on glycoprotein properties,” BioTechnology 9:1347-1355 (1991).Applicant
• Gottleib et al., “The safety of intravitreal hyaluronidase. A clinical and histologic study,” Invest Ophthalmol Vis Sci 31:(11)2345-2352 (1990).Applicant
• Gribskov et al., “Sigma factors from E. coli, B. subtilis, phage SP01, and phage T4 are homologous proteins,” Nucl. Acids Res. 14(16):6745-6763 (1986).Applicant
• Grosschedl et al., “Introduction of a mu immunoglobulin gene into the mouse germ line: specific expression in lymphoid cells and synthesis of functional antibody,” Cell 38:647-658 (1984).Applicant
• Grossman, M. and J. Wilson, “Retroviruses: delivery vehicle to the liver,” Curr. Opin. In Genetics And Devel. 3:110-114 (1993).Applicant
• Grunstein, M. and D. Hogness, “Colony hybridization: a method for the isolation of cloned DNAs that contain a specific gene,” Proc. Natl. Acad. Sci. U.S.A. 72(10):3961-3965 (1975).Applicant
• Guntenhoner et al., “A substrate-gel assay for hyaluronidase activity,” Matrix 12:388-396 (1992).Applicant
• Guo et al., “Protein tolerance to random amino acid change,” Proc. Nat'l. Acad. Sci. USA, 101:9205-9210, 2004.Applicant
• Hahm et al., “Generation of a novel poliovirus with a requirement of hepatitis C virus protease NS3 activity,” Virology 226:318-326 (1996).Applicant
• Haller et al., “Escaping the interstitial matrix with enzyme-mediated drug delivery,” Drug Delivery Technology 5(5):1-6 (2005).Applicant
• Haller, M., “Converting intravenous dosing to subcutaneous dosing with recombinant human hyaluronidase,” Pharmaceut Tech. Newsletter, Oct. 2007, 14 pgs.Applicant
• Hallgren et al, “Accumulation of hyaluronan (hyaluronic acid) in myocardial interstitial tissue parallels development of transplantation edema in heart allografts in rats,” J Clin Invest 85:668-673 (1990).Applicant
• Hallgren et al, “Hyaluronic acid accumulation and redistribution in rejecting rat kidney graft. Relationship to the transplantation edema,” J Exp Med. 171:2063-2076 (1990).Applicant
• Hallgren et al., “Accumulation of hyaluronan (hyaluronic acid) in the lung in adult respiratory distress syndrome,” Am Rev Respzr Dis. 139(3):682-687 (1989).Applicant
• Hamatake et al., “Establishment of an in vitro assay to characterize hepatitis C virus NS3-4A protease trans-processing activity,” Intervirology 39:249-258 (1996).Applicant
• Hamilton et al., “A species of small antisense RNA in posttranscriptional gene silencing in plants,” Science 286:950-952 (1999).Applicant
• Hammer et al., “Diversity of alpha-fetoprotein gene expression in mice is generated by a combination of separate enhancer elements,” Science 235:53-58 (1987).Applicant
• Hammond et al., “An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells,” Nature 404:293-296 (2000).Applicant
• Hammond et al., “Post-transcriptional gene silencing by double-stranded RNA,” Nature Rev Genet. 2:110-119 (2001).Applicant
• Hanahan, D., “Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes,” Nature (3)15:115-122 (1985).Applicant
• Harrison, R., “Hyaluronidase in Ram Semen,” Biochem. J. 252:865-874 (1988).Applicant
• Hartman S. and R. Mulligan, “Two dominant-acting selectable markers for gene transfer studies in mammalian cells,” Proc Natl Acad Sci 85:8047-8051 (1988).Applicant
• Haselbeck, et al., “Immunological detection of glycoproteins on blots based on labeling with digoxigenin,” Methods in Mol. Biol. 14:161-173 (1993).Applicant
• Heldin, P., “Importance of hyaluronan biosynthesis and degradation in cell differentiation and tumor formation,” Brazilian J. Med. Biol. Res. 36:967-973 (2003).Applicant
• Herrera-Estrella et al., “Expression of chimaeric genes transferred into plant cells using a ti-plasmid-derived vector,” Nature 303:209-213 (1984).Applicant
• Herrera-Estrella et al., “Light-inducible and chloroplast-associated expression of a chimaeric gene introduced into Nicotiana tabacum using a Ti plasmid vector,” Nature 310(5973):115-120 (1984).Applicant
• Hiyama K. and S. Okada, “Action of chondroitinases. I. The mode of action of two chondroitinase-AC preparations of different origin,” J. Biochem. (Tokyo) 80:1201 (1976).Applicant
• Hiyama, K. and S. Okada, “Crystallization and some properties of chondroitinase from Arthrobacter aurescens,” J. Biol. Chem. 250:1824-1828 (1975).Applicant
• Hooper et al., “Determination of glycosyl-phosphatidylinositol membrane protein anchorage” Proteomics 1:748-755 (2001).Applicant
• Horn et al., “Intravesical chemotherapy of superficial bladder tumors in a controlled trial with cis-platinum versus cis-platinum plus hyaluronidase,” J. Surg. Oncol. 28:304-307 (1985).Applicant
• Hunkapiller et al, “A microchemical facility for the analysis and synthesis of genes and proteins,” Nature 310:105-111 (1984).Applicant
• Hunnicut et al., “Structural relationship of sperm soluble hyaluronidase to the sperm membrane protein PH-20,” Biol Reprod. 54(6):1343-1349 (1996).Applicant
• Hutchison et al., “Mutagenesis at a specific position in a DNA sequence,” J. Biol. Chem. 253:6551-6560 (1978).Applicant
• Inoue et al., “Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H,” FEBS Lett. 215:327-330 (1987).Applicant
• Inoue et al., “Synthesis and hybridization studies on two complementary nona(2′-O-methyl)ribonucleotides,” Nucl. Acids Res. 15:6131-6148 (1987).Applicant
• Ishikawa et al., “Action of chondroitinase ABC on epidurally transplanted nucleus pulposus in the rabbit,” Spine. 24(11):1071-1076 (1999).Applicant
• Ito et al., “Cultivation of hepatitis C virus in primary hepatocyte culture from patients with chronic hepatitis C results in release of high titre infectious virus,” J. Gen. Virol. 77:1043-1054 (1996).Applicant
• IUPAC-IUB, “Commission on biochemical nomenclature abbreviated nomenclature of synthetic polypeptides (Polymerized Amino Acids),” Biochemistry 11:942-944 (1972).Applicant
• Kaiser, K. and N. Murray, “The use of phage lambda replacement vectors in the construction of representative genomic DNA libraries.” In DNA Cloning: A Practical Approach (Ed. D. Glover). 1985, MRL Press, Ltd., Oxford, U. K., 1985. vol. 1 pp. 11-12.Applicant
• Kanamori et al., “Deaminated neuraminic acid-rich glycoprotein of rainbow trout egg vitelline envelope. Occurrence of a novel alpha-2,8-linked oligo(deaminated neuraminic acid) structure in O-linked glycan chains,” J. Biol. Chem. 265:21811-21819 (1990).Applicant
• Kelsey et al., “Species- and tissue-specific expression of human alpha 1-antitrypsin in transgenic mice,” Genes And Devel. 1:161-171 (1987).Applicant
• Kiem et al., “Retrovirus-mediated gene transduction into canine peripheral blood repopulating cells,” Blood 83:1467-1473 (1994).Applicant
• Kimata et al., “Increased synthesis of hyaluronic acid by mouse mammary carcinoma cell variants with high metastatic potential,” Cancer Res. 43: 1347-1354 (1983).Applicant
• Klocker et al., “Combined Application of Cisplatin, Vindesine, Hyaluronidase and Radiation for Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck” Am. J. Clin. Oncol. 18: 425-428 (1995).Applicant
• Knudson et al, “Hyaluronan-binding proteins in development, tissue homeostasis, and disease,” FASEB J. 7:1233-1241 (1993).Applicant
• Kodo et al., “Antibody synthesis by bone marrow cells in vitro following primary and booster tetanus toxoid immunization in humans,” J. Clin. Invest. 73:1377-1384 (1984).Applicant
• Kodukula et al., “Biosynthesis of Phosphatidylinositol Glycan-anchored Membrane Proteins” J. Biol. Chem. 266:4464-4470 (1991).Applicant
• Kohler, G. and C. Milstein, “Continuous cultures of fused cells secreting antibody of predefined specificity,” Nature 256:495-497 (1975).Applicant
• Kohno et al., “Effects of hyaluronidase on doxorubicin penetration into squamous carcinoma multicellular tumor spheroids and its cell lethality,” J. Cancer Res. Oncol. 120:293-297 (1994).Applicant
• Koller, B. and O. Smithies, “Inactivating the beta 2-microglobulin locus in mouse embryonic stem cells by homologous recombination,” Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989).Applicant
• Kollias et al., “Regulated expression of human A gamma-, beta-, and hybrid gamma beta-globin genes in transgenic mice: manipulation of the developmental expression patterns,” Cell 46:89-94 (1986).Applicant
• Kolodgie et al, “Differential accumulation of proteoglycans and hyaluronan in culprit lesions: insights into plaque erosion,” Arterioscler Thromb Vasc Biol. 22(10):1642-1648 (2002).Applicant
• Kozak et al., “The effect of recombinant human hyaluronidase on dexamethasone penetration into the posterior segment of the eye after sub-tenon's injection,” Journal of Ocular Pharmacology and Therapeutics, 22(5):362-369 (2006).Applicant
• Kozak J., “Structural features in eukaryotic mRNAs that modulate the initiation of translation,” J Biol. Chem. 266:19867-19870 (1991).Applicant
• Kozarsky, K. and J. Wilson, “Gene therapy: adenovirus vectors,” Current Opinion in Genetics and Development 3:499-503 (1993).Applicant
• Kriel, K., “Hyaluronidases—a group of neglected enzymes,” Protein Sci. 4(9):1666-1669 (1995).Applicant
• Krol et al., “Modulation of eukaryotic gene expression by complementary RNA or DNA sequences,” BioTechniques 6:958-976 (1988).Applicant
• Kroll et al., “A multifunctional prokaryotic protein expression system: overproduction, affinity purification, and selective detection,” DNA Cell Biol 12:441-453 (1993).Applicant
• Krumlauf et al., Developmental regulation of alpha-fetoprotein genes in transgenic mice, Mol. Cell. Biol. 5:1639-1648 (1985).Applicant
• Krupers et al., “Complexation of poly(ethylene oxide) with poly(acrylic acid-co-hydroxyethyl methacrylate)s,” Eur. Polym J. 32:785-790, 1996).Applicant
• Kyte et al., “A Simple Method for Displaying the Hydropathic Character of a Protein” J. Mol. Biol. 157:105-132 (1982).Applicant
• Lalancette et al, “Characterization of an 80-kilodalton bull sperm protein identified as PH-20,” Biol Reprod. 65(2):628-636 (2001).Applicant
• Larsson et al., “Hyaluronic acid (hyaluronan) in BAL fluid distinguishes farmers with allergic alveolitis from farmers with asymptomatic alveolitis,” Chest. 101(1):109-114 (1992).Applicant
• Lathrop et al., “cDNA cloning reveals the molecular structure of a sperm surface protein, PH-20, involved in sperm-egg adhesion and the wide distribution of its gene among mammals,” J Cell Biol. 111(6 Pt 2):2939-2949 (1990).Applicant
• Laurent et al, “Hyaluronan in human cerebrospinal fluid,” Acta Neurol Scand 94(3):194-206 (1996).Applicant
• Laurent, T. and J. Fraser, “Hyaluronan,” FASEB J 6:2397-2404 (1992).Applicant
• Leder et al., “Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development,” Cell 45:485-495 (1986).Applicant
• Lemaitre et al., “Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site,” Proc. Natl. Acad. Sci. USA 84:648-652 (1987).Applicant
• Letsinger et al., “Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture,” Proc. Natl. Acad. Sci. USA 86:6553-6556 (1989).Applicant
• Levine, J., “Increased expression of the NG2 chondroitin-sulfate proteoglycan after brain injury,” J Neurosci. 14(8):4716-4730 (1994).Applicant
• Li et al., “Irradiation-induced expression of hyaluronan (HA) synthase 2 and hyaluronidase 2 genes in rat lung tissue accompanies active turnover of HA and induction of types I and III collagen gene expression,” Am. J. Respir. Cell Mol. Biol. 23:411-418 (2000).Applicant
• Lin et al., “A hyaluronidase activity of the sperm plasma membrane protein PH-20 enables sperm to penetrate the cumulus cell layer surrounding the egg,” J Cell Biol. 125(5):1157-1163 (1994).Applicant
• Lin et al., “Molecular cloning of the human and monkey sperm surface protein PH-20,” Proc. Natl. Acad. Sci. USA 90:10071-10075 (1993).Applicant
• Lin, Y. “Characterization of the sperm surface protein PH-20 as an antigen for a contraceptive vaccine,” (Jan. 1, 1994) Dissertations Collection for University of Connecticut. Paper AAI9423832, 182 pages.Applicant
• Loeffler, J. and J. Behr, “Gene transfer into primary and established mammalian cell lines with lipopolyamine-coated DNA,” Meth. Enzymol. 217:599-618 (1993).Applicant
• Low et al., “Biochemistry of the glycosyl-phosphatidylinositol membrane protein anchors,” Biochem. J. 224:1-13 (1987).Applicant
• Lowy et al., “Isolation of transforming DNA: cloning the hamster aprt gene,” Cell 22:817-823 (1980).Applicant
• Lu, H. and E. Wimmer., “Poliovirus chimeras replicating under the translational control of genetic elements of hepatitis C virus reveal unusual properties of the internal ribosomal entry site of hepatitis C virus,” Proc. Natl. Acad. Sci. USA 93:1412-1417 (1996).Applicant
• Macdonald, R., “Expression of the pancreatic elastase I gene in transgenic mice,” Hepatology 7:425-515(1987).Applicant
• Maclean et. al., “Hyaluronidase-induced reductions in myocardial infarct size,” Science 194(4261):199-200 (1976).Applicant
• Maeyama et al., “Chondroitinase AC—a unique illegible structure of ABC,” Seikagaku 57:1189 (1985). [Certified English translation].Applicant
• Magram et al., “Developmental regulation of a cloned adult beta-globin gene in transgenic mice,” Nature 315:338-340 (1985).Applicant
• Mammalian Gene Collection (MGC) Program Team, “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences,” Proc. Natl. Acad. Sci. USA 99:16899-16903 (2002).Applicant
• Mantovani et al., “Efficacy of varying concentrations of hyaluronidase in peribulbar anaesthesia,” British J. Anaesthesia 86:876-878 (2001).Applicant
• Mantyh et al., “Inhibition of hyperalgesia by ablation of lamina 1 spinal neurons expressing the substance P receptor,” Science 278:275-279 (1997).Applicant
• Maroko et al., “Reduction by hyaluronidase of myocardial necrosis following coronary occlusion,” Circulation 46:430-437 (1972).Applicant
• Mason et al., “The hypogonadal mouse: reproductive functions restored by gene therapy,” Science 234:1372-1378 (1986).Applicant
• Mastrangeli et al., “Diversity of airway epithelial cell targets for in vivo recombinant adenovirus-mediated gene transfer,” J. Clin. Invest. 91:225-234 (1993).Applicant
• Mckeon et al., “Reduction of neurite outgrowth in a model of glial scarring following CNS injury is correlated with the expression of inhibitory molecules on reactive astrocytes,” J Neurosci. 11(11):3398-3411 (1991).Applicant
• Menzel, E. and C. Farr, “Hyaluronidase and its substrate hyaluronan: biochemistry, biological activities and therapeutic uses,” Cancer Lett., 131:3-11 (2003).Applicant
• Merrifield, J., “Solid phase peptide synthesis. I. The synthesis of a tetrapeptide,” J Am Chem Soc 85:2149-2154 (1963).Applicant
• Meyer, K., “Hyaluronidases,” In: The Enzymes, 3rd Edition, Boyer, P. (Ed.), New York:Academic Press, 307-320 (1971).Applicant
• Meyer et al., “The soluble hyaluronidase from bull testes is a fragment of the membrane-bound PH-20 enzyme.” FEBS Letters 413(2):385-388 (1997).Applicant
• Michelacci, Y. and C. Dietrich, “Isolation and partial characterization of an induced chondroitinase B from Flavobacterium heparinum,” Biochem. Biophys. Res. Commun. 56:973-980 (1974).Applicant
• Michelacci, Y. and C. Dietrich, “A comparative study between a chondroitinase B and a chondroitinase AC from Flavobacterium heparinum: Isolation of a chondroitinase AC-susceptible dodecasaccharide from chondroitin sulphate B,” Biochem. J. 151:121-129 (1975).Applicant
• Milev et al., “Interactions of the chondroitin sulfate proteoglycan phosphacan, the extracellular domain of a receptor-type protein tyrosine phosphatase, with neurons, glia, and neural cell adhesion molecules,” J Cell Biol. 127(6 Pt 1):1703-1715 (1994).Applicant
• Miller et al., “Use of retroviral vectors for gene transfer and expression,” Meth. Enzymol. 217:581-599 (1993).Applicant
• Mitani, K. and C. Caskey, “Delivering therapeutic genes—matching approach and application,” TIBTECH 11(5):162-166 (1993).Applicant
• Miyazono et al., “A structural analysis of the sugar chain (II),” Seikagaku 61:1023 (1989). [Certified English translation].Applicant
• Mizutani et al., Characterization of hepatitis C virus replication in cloned cells obtained from a human T-cell leukemia virus type 1-infected cell line, MT-2, J.Virol. 70:7219-7223 (1996).Applicant
• Mizutani et al., “Inhibition of hepatitis C virus replication by antisense oligonucleotide in culture cells,” Biochem. Biophys. Res. Commun. 212:906-911 (1995).Applicant
• Mizutani et al., “Long-term human T-cell culture system supporting hepatitis C virus replication,” Biochem. Biophys. Res. Commun. 227:822-826 (1996).Applicant
• Morgan, R. and W. Anderson, “Human gene therapy,” An. Rev. Biochem. 62:191-217 (1993).Applicant
• Mulligan, R., “The basic science of gene therapy,” Science 260:926-932 (1993).Applicant
• Nabel et al., “Direct gene transfer for immunotherapy and immunization,” TIBTECH 11:211-215 (1993).Applicant
• Nadano et al., “A naturally occurring deaminated neuraminic acid, 3-deoxy-D-glycero-D-galacto-nonulosonic acid (KDN). Its unique occurrence at the nonreducing ends of oligosialyl chains in polysialoglycoprotein of rainbow trout eggs,” J. Biol. Chem. 261:11550-11557 (1986).Applicant
• Needleman, S. and C. Wunsch “A general method applicable to the search for similarities in the amino acid sequence of two proteins,” J Mol Biol. 48:443 (1970).Applicant
• Nettelbladt et al, “Accumulation of hyaluronic acid in the alveolar interstitial tissue in bleomycin-induced alveolitis,” Am Rev Resp Dis 139:759-762 (1989).Applicant
• Nogrady, T., Medicinal Chemistry A Biochemical Approach, 30 Oxford University Press, New York, pp. 388-392 (1985).Applicant
• O'Reilly, M., “The preclinical evaluation of angiogenesis inhibitors,” Invest New Drugs 15(1): 5-13 (1997).Applicant
• Oettl et al. “Comparative characterization of bovine testicular hyaluronidase and a hyaluronate lyase from Streptococcus agalactiae in pharmaceutical preparations,” Eur. J. Pharm. Sci. 18:267-277 (2003).Applicant
• Ornitz et al., “Elastase I promoter directs expression of human growth hormone and SV40 T antigen genes to pancreatic acinar cells in transgenic mice,” Cold Spring Harbor Symp. Quant. Biol. 50:399-409 (1986).Applicant
• Ozzello et al., “Growth-promoting activity of acid mucopolysaccharides on a strain of human mammary carcinoma cells,” Cancer Res. 20:600-604 (1960).Applicant
• Paul, A. and D. Sochart, “Improving the results of ganglion aspiration by the use of hyaluronidase,” J Hand Surg 22(2):219-221 (1997).Applicant
• Pawlowski et al., “The effects of hyalurodinase upon tumor formation in BALB/c mice painted with 7,12-dimethylbenz-(a)anthracene,” Int. J. Cancer 23:105-109 (1979).Applicant
• Pearson, W. and D. Lipman “Improved tools for biological sequence comparison,” Proc. Natl. Acad. Sci. USA 85:2444 (1988).Applicant
• Phelps et al., “Restricted lateral diffusion of PH-20, a PI-anchored sperm membrane protein,” Science 240:1780-1782 (1988).Applicant
• Pinkert et al., “An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice,” Genes and Devel. 1:268-276 (1987).Applicant
• Pirrello et al., “Initial experiences with subcutaneous recombinant human hyaluronidase,” J Palliat Med. Aug. 2007;10(4):861-4.Applicant
• Pittelkow, M. and R. Scott, “New techniques for the in vitro culture of human skin keratinocytes and perspectives on their use for grafting of patients with extensive burns,” Clinic Proc. 61:771-777 (1986).Applicant
• Porath, J., “Immobilized metal ion affinity chromatography,” Protein Expression and Purification 3:263-281 (1992).Applicant
• Porteous et al., “How relevant are mouse models for human diseases to somatic gene therapy?” TIBTECH 11:173-181 (1993).Applicant
• Powell et al., “Mechanisms of astrocyte-directed neurite guidance,” Cell Tissue Res. 290(2):385-393 (1997).Applicant
• Powell, E. and H. Geller, “Dissection of astrocyte-mediated cues in neuronal guidance and process extension,” Glia. 26(1):73-83 (1999).Applicant
• Ramsden et al, “A new disorder of hyaluronan metabolism associated with generalized folding and thickening of the skin,” J. Pediatr. 136:62-68 (2000).Applicant
• Readhead et al., “Expression of a myelin basic protein gene in transgenic shiverer mice: correction of the dysmyelinating phenotype,” Cell 48:703-712 (1987).Applicant
• Rheinwald, J., “Serial cultivation of normal human epidermal keratinocytes,” Meth. Cell Bio. 21A:229-254 (1980).Applicant
• Rhodes et al., “Transformation of maize by electroporation of embryos,” Methods Mol Biol 55:121-131 (1995).Applicant
• Roberts et al., “Heparan sulphate bound growth factors: a mechanism for stromal cell mediated haemopoiesis,” Nature 332(6162):376-378 (1988).Applicant
• Robinson, C., “Gene therapy—proceeding from laboratory to clinic,” TIBTECH 11:155 (1993).Applicant
• Rodbard et al., “Statistical characterization of the random errors in the radioimmunoassay dose—response variable,” Clin. Chem. 22:350-358 (1976).Applicant
• Rosenfeld et al., “Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo,” Science 252:431-434 (1991).Applicant
• Rosenfeld et al., “In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium,” Cell 68:143-155 (1992).Applicant
• Ruoslahti, E. and Y. Yamaguchi, “Proteoglycans as modulators of growth factor activities,” Cell 64(5):867-869 (1991).Applicant
• Saito et al., “Enzymatic methods for the determination of small quantities of isomeric chondroitin sulfates,” J. Biol. Chem. 243:1536-1542 (1968).Applicant
• Salmons, B. and W. Gunzberg, “Targeting of retroviral vectors for gene therapy,” Human Gene Therapy 4:129-141 (1993).Applicant
• Saltus, R. and Globe Staff, “Shortages of drugs have hospitals scrambling,” The Boston Globe, Jan. 9, 2001. 3 pages.Applicant
• Sambrook et al., in: Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press vol. 3, p. B. 13 (1989).Applicant
• Sarin et al., “Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates,” Proc. Natl. Acad. Sci. USA 85:7448-7451 (1988).Applicant
• Sarver et al., “Ribozymes as potential anti-HIV-1 therapeutic agents,” Science 247:1222-1225 (1990).Applicant
• Sasaki et al., “Effects of chondroitinase ABC on intradiscal pressure in sheep: an in vivo study,” Spine 26(5):463-468 (2001).Applicant
• Sawhney et al., “Bioerodible hydrogels based on photopolymerized poly(ethylene glycol)-co poly(hydroxyl acid) Diacrylate Macromers,” Macromolecules 26:581-587 (1993).Applicant
• Scharf et al., “Heat stress promoters and transcription factors,” Results Probl Cell Differ 20:125-162 (1994).Applicant
• Scheithauer et al., “In vitro evaluation of the anticancer drug modulatory effect of hyaluronidase in human gastrointestinal cell lines,” Anticancer Res. 8:391-396 (1988).Applicant
• Schuller et al., “Pharmacokinetics of intrahepatic 5-fluorouracil + preinjected hyaluronidase,” Proc. Amer. Assoc. Cancer Res. 32:173, abstract No. 1034 (1991).Applicant
• Schwartz, R. and M. Dayhoff, eds., Atlas Of Protein Sequence And Structure, National Biomedical Research Foundation, pp. 353-358 (1979).Applicant
• Schwartzman, J., “Hyaluronidase: A Review in Its Therapeutic Use in Pediatrics,” J. Pediat. 39:491-502 (1951).Applicant
• Seaton et al., “Rat sperm 2B1 glycoprotein (PH20) contains a C-terminal sequence motif for attachment of a glycosyl phosphatidylinositol anchor. Effects of endoproteolytic cleavage on hyaluronidase activity,” Biol Reprod. 62(6):1667-1676 (2000).Applicant
• Sequence Alignment [online], Blast2 alignment from U.S. Appl. No. 12/378,984 SEQ ID No. 1 with the polypeptide of GenBank record No. P38567 [retrieved on Apr. 18, 2011] [retrieved from the Internet:<URL:blast.ncbi.nlm.nih.gov/Blast.cgi], 2 pages.Applicant
• Sequence alignments from U.S. Appl. No. 10/795,095 search of SEQ ID No. 1 in the Issued Patents database, performed on Sep. 25, 2007, 13 pages.Applicant
• Shani, M., “Tissue-specific expression of rat myosin light-chain,” Nature 314:283-286 (1985).Applicant
• Sharp, P., “RNA interference—2001,” Genes Dev. 15:485-490 (2001).Applicant
• Shekhar et al., “The matrix reloaded: Halozyme's recombinant enzyme helps injected drugs spread faster,” Chem. Biol. 14:603-604 (2007).Applicant
• Shilo, B. and R. Weinberg, “DNA sequences homologous to vertebrate oncogenes are conserved in Drosophila melanogaster,” Proc. Natl. Acad Sci USA 78:6789-6792 (1981).Applicant
• Shimizu, Y. and H. Yoshikura, “Multicycle infection of hepatitis C virus in cell culture and inhibition by alpha and beta interferons,” J. Virol. 68:8406-8408 (1994).Applicant
• Shuster et al., “Hyaluronidase reduces human breast cancer xenografts in SCID mice,” Int. J. Cancer 102:192-197 (2002).Applicant
• Sikora, K. “Gene therapy for cancer,” TIBTECH 11(5):197-201 (1993).Applicant
• Smith, D. and K. Johnson, “Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase,” Gene 7:31-40 (1988).Applicant
• Smith, T. and M. Waterman, “Comparison of biosequences,” Advances in Applied Mathematics 2:482-489 (1981).Applicant
• Snow et al., “Immunolocalization of heparan sulfate proteoglycans to the prion protein amyloid plaques of Gerstmann-Straussler syndrome, Creutzfeldt-Jakob disease and scrapie,” Lab Invest. 63(5):601-611 (1990).Applicant
• Snow, D. and P. Letourneau, “Neurite outgrowth on a step gradient of chondroitin sulfate proteoglycan (CS-PG,” J Neurobiol. 23(3):322-336 (1992).Applicant
• Spatola, A., “Peptide backbone modifications,” in Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins, Weistein, B., Ed., vol. 7, Marcel Dekker:New York, pp. 267-357 (1983).Applicant
• Specification Sheet, Phosphate Buffered Saline[online][retrieved on Sep. 1, 2010 from: <URL:sigmaaldrich.com/catalog/DataSheetPage.do?brandKey=SIGMA&symbol=P4417], 1 page.Applicant
• St Croix et al., “Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors,” Cancer Lett 131(1):35-44 (1998).Applicant
• Stein et al., “Physicochemical properties of phosphorothioate oligodeoxynucleotides,” Nucl. Acids Res. 16:3209 (1988).Applicant
• Steinkuhler et al., “Design of selective eglin inhibitors of HCV NS3 proteinase,” Biochem. 37(33):11459-11468 (1998).Applicant
• Stemple, D. and D. Anderson, “Isolation of a stem cell for neurons and glia from the mammalian neural crest,” Cell 71:973-985 (1992).Applicant
• Stern, R., “Devising a pathway for hyaluronan catabolism: are we there yet?” Glycobiology 13:105R-115R (2003).Applicant
• Stryer, L., Ed.,“Part I, molecular design of life,” Stryer Biochemistry, W.H. Freeman and Company: NY, Third Edition, pp. 18-20 (1988).Applicant
• Sudo et al., “Establishment of an in vitro assay system for screening hepatitis C virus protease inhibitors using high performance liquid chromatography,” Antiviral Res. 32:9-18 (1996).Applicant
• Suzuki et al., “Formation of three types of disulfated disaccharides from chondroitin sulfates by chondroitinase digestion,” J. Biol. Chem. 243:1543-1550 (1968).Applicant
• Swift et al., “Tissue-specific expression of the rat pancreatic elastase I gene in transgenic mice,” Cell 38:639-646 (1984).Applicant
• Takeshita et al., “An enzyme-linked immunosorbent assay for detecting proteolytic activity of hepatitis C virus proteinase,” Anal. Biochem. 247:242-246 (1997).Applicant
• Takeuchi et al., “Variation in glycosaminoglycan components of breast tumors,” Cancer Res. 36:2133-2139 (1976).Applicant
• Taliani et al., “A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrates,” Anal. Biochem. 240:60-67 (1996).Applicant
• Tolstoshev, P., “Gene therapy, concepts, current trials and future directions,” An. Rev. Phmacol. Toxicol. 32:573-596 (1993).Applicant
• Tomita, M., “Background of Paroxysmal Nocturnal Hemoglobinuria,” BiochemicalBiochim. Biophys. Acta 1455:269-286 (1997).Applicant
• Toole, B., “Proteoglycans and hyaluronan in morphogenesis and differentiation,” Cell Biol. Extracell. Matrix, Hay (ed), Plenum Press:New York 305-341 (1991).Applicant
• Townsend et al., “Separation of branched sialylated oligosaccharides using high-pH anion-exchange chromatography with pulsed amperometric detection,” Anal. Biochem. 182:1-8 (1989).Applicant
• Townsend, et al, “Analysis of glycoconjugates using high-ph anion-exchange chromatography,” in Carbohydrate Analysis: High-perfonnance liquid chromatography and capillary electrophoresis (Z. El Rassi ed.). pp. 181-209 (1995).Applicant
• Tuschl, T., “RNA interference and small interfering RNAs,” Chem. Biochem. 2:239-245 (2001).Applicant
• Tyle, P., “Iontophoretic devices for drug delivery,” Pharmaceutical Research 3(6):3-18 (1986).Applicant
• Tyndel, M., “Hyaluronidase as an adjuvant in insulin shock therapy” J Am Med Assoc,162(1):32-34 (1956).Applicant
• UniProt Murine PH20 sequence, Published on Jul. 13, 2010 [online][retrieved on Aug. 2, 2010] Retrieved from:<URL:uniprot.org/uniprot/P48794 [5 pages].Applicant
• Van Halbeek, H., “1H nuclear magnetic resonance spectroscopy of carbohydrate chains of glycoproteins,” Methods Enzymol 230:132-168 (1994).Applicant
• Varki, A., “Diversity in the sialic acids,” Glycobiology 2: 25-40; Sialic Acids: Chemistry, Metabolism and Function, R. Schauer, Ed. (Springer-Verlag, N.Y. (1992)).Applicant
• Villa-Kamaroff et al., “A bacterial clone synthesizing proinsulin,” Proc. Natl. Acad. Sci. USA 75:3727-3731 (1978).Applicant
• Waeghe et al., “Determination, by methylation analysis, of the glycol-syl-linkage compositions of microgram quantities of complex carbohydrates,” Carbohydr Res. 123:281-304 (1983).Applicant
• Wagner et al., “Nucleotide sequence of the thymidine kinase gene of herpes simplex virus type 1,” Proc. Natl. Acad. Sci. USA 78:1441-1445 (1981).Applicant
• Waldenstrom et al., “Accumulation of hyaluronan and tissue edema in experimental myocardial infarction,” J Clin Invest 88(5):1622-1628 (1991).Applicant
• Waldenstrom et al., “Coxsackie B3 myocarditis induces a decrease in energy charge and accumulation of hyaluronan in the mouse heart,” Eur J Clin Invest 23:277-282 (1993).Applicant
• Wallander et al., “Intestinal distribution of hyaluronan in small bowel allografting in the rat,” Transplant Int 6:133-137 (1993).Applicant
• Walsh et al., “Gene therapy for human hemoglobinopathies,” Proc. Soc. Exp. Biol. Med. 204:289-300 (1993).Applicant
• Watson et al., Molecular Biology of the Gene, 4th Edition, The Benjamin/Cummings Pub. Co., p. 224 (1987).Applicant
• Weitzhandler et al, “Monosaccharide and oligosaccharide analysis of proteins transferred to polyvinylidene fluoride membranes after sodium dodecyl sulfate-polyacrylamide gel electrophoresis,” J. Biol. Chem. 268:5121-5130 (1993).Applicant
• Wells et al., “The localization of hyaluronan in normal and rejected human kidneys,” Transplantation 50:240-243 (1990).Applicant
• West et al., “The effect of hyaluronate and its oligosaccharides on endothelial cell proliferation and monolayer integrity,” Exp. Cell. Res. 183:179-196 (1989).Applicant
• Whitlock, C. and O. Witte, “Long-term culture of B lymphocytes and their precursors from murine bone marrow,” Proc. Natl. Acad. Sci. USA 79:3608-3612 (1982).Applicant
• Wigler et al., “Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells,” Cell 11:223-232 (1977).Applicant
• Wigler et al., “Transformation of mammalian cells with an amplifiable dominant-acting gene,” Proc Natl Acad Sci. USA 77:3567-3570 (1980).Applicant
• Williams, R., “The Effects of Continuous Local Injection of Hyaluronidase on Skin and Subcutaneous Tissue in Rats,” Anat. Rec. 122:349-361 (1955).Applicant
• Williamson, R., “From genome mapping to gene therapy,” TIBTECH 11(5):159-161 (1993).Applicant
• Wivel, N., “Regulatory considerations for gene-therapy strategies and products,” TIBTECH 11(5):189-191 (1993).Applicant
• Wolf, et. al., “The serum kinetics of bovine testicular hyaluronidase in dogs, rats and humans,” J Pharmacol Exp Ther 222(2):331-337 (1982).Applicant
• World Health Organization (WHO) guideline: cf. D21, WHO Technical Report Series, No. 184 “Guidelines for assuring the quality of pharmaceutical and biological products prepared by recombinant DNA technology,” (1991).Applicant
• Wu, G. and C. Wu, “Receptor-mediated in vitro gene transformation by a soluble DNA carrier system,” J. Biol. Chem, 262:4429-4432 (1987).Applicant
• Wu, G. and C. Wu, “Delivery systems for gene therapy,” Biotherapy 3:87-95 (1991).Applicant
• Yamagata et al., “Purification and properties of bacterial chondroitinases and chondrosulfatases,” J. Biol. Chem. 243: 1523-1535 (1968).Applicant
• Yamamoto et al., “Identification of a functional promoter in the long terminal repeat of Rous sarcoma virus,” Cell 22:787-797 (1980).Applicant
• Yocum et al., “Assessment and Implication of the Allergic Sensitivity to a Single Dose of Recombinant Human Hyaluronidase Injection: A Double-Blind Placebo-Controlled Clinical Trial,” J Infus Nursing. 30:293-299 (2007).Applicant
• Yudin et al., “Characterization of the active site of monkey sperm hyaluronidase,” Reproduction. 121(5):735-743 (2001).Applicant
• Zalipsky, S. and C. Lee, “Poly(ethylene glycol) Chemistry: Biotechnical and Biomedical Applications,” J.M. Hams, ed., Plenum, NY, chapter 21, pp. 347-370 (1992).Applicant
• Zalipsky, S., “Chemistry of polyethylene glycol conjugates with biologically active molecules,” Adv. Drug Del. Rev. 16:157-182 (1995).Applicant
• Zamore et al., “RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals,” Cell 101:25-33 (2000).Applicant
• Zanker et al., “Induction of response in previous chemotherapy resistant patients by hyaluronidase,” Proc. Amer. Assoc. Cancer Res. 27:390 Abstract 1550 (1986).Applicant
• Zhao, X. and J. Harris, “Novel degradable poly(ethylene glycol) esters for delivery,” in Poly(ethylene glycol), Chemistry and Biological Applications, ACS Symposium Series 680, Hams, J. and S. Zalipsky, (eds), 458-472 (1997).Applicant
• Zijlstra et al., “Germ-line transmission of a disrupted beta 2-microglobulin gene produced by homologous recombination in embryonic stem cells,” Nature 342:435-438 (1989).Applicant
• Zon, G., “Oligonucleotide analogues as potential chemotherapeutic agents,” Pharm. Res. 5:539-549 (1988).Applicant
• Bee et al., “Recombinant human PH20 is well tolerated at higher intravenous and subcutaneous doses in cynomolgus monkeys,” EUFEPS 2008, Munich, Germany, abstract, 2 pages.Applicant
• Bee et al., “Recombinant human PH20 is well tolerated at higher intravenous and subcutaneous doses in cynomolgus monkeys,” EUFEPS 2008, Munich, Germany, poster, 1 page.Applicant
• Bookbinder et al., “Biochemical characterization of recombinant human PH20 (SPAM1) hyaluronidase,” Hyaluronan (ISHAS) 2007, Charleston, SC, abstract, 1 page.Applicant
• Bookbinder et al., “Biochemical characterization of recombinant human PH20 (SPAM1) hyaluronidase,” Hyaluronan (ISHAS) 2007, Charleston, SC, poster, 1 page.Applicant
• Bookbinder et al., “Enhancing drug transport through temporary matrix depolymerization,” Keystone Symposium 2005, abstract, 1 page.Applicant
• Pinkstaff et al., “Enhancing drug transport through temporary matrix depolymerization,”, Keystone Symposium 2005, poster, 12 pages.Applicant
• Bookbinder et al., “Evaluation of the compatibility and pharmacokinetics of co-formulated biologics with recombinant human hyaluronidase: dose response,” American Association of Pharmaceutical Scientists Conference, Nov. 2006, abstract, 2 pages.Applicant
• Pinkstaff et al., “Evaluation of the compatibility and pharmacokinetics of co-formulated biologics with recombinant human hyaluronidase: dose response,” American Association of Pharmaceutical Scientists Conference, Nov. 2006, poster, 1 page.Applicant
• Byerley et al., “‘Cutting out the bull’. Recombinant human hyaluronidase: Moving to an animal-free system,” Association of Clinical Embryologists, 2006, Dublin, Ireland. Abstract published in Human Fertility, 9(2):110 (2006).Applicant
• Frost et al., “Punctuated equilibrium: The evolution of recombinant human hyaluronidase,” Ophthalmic Anesthesia Society, 2006, Chicago, IL, 1 page.Applicant
• Frost et al., “Punctuated equilibrium: The evolution of recombinant human hyaluronidase,” Ophthalmic Anesthesia Society, 2006, Chicago, IL, presentation, 35 pages.Applicant
• Haller et al., “Recombinant human hyaluronidase for the interstitial transport of therapeutics,” American Association of Pharmaceutical Scientists Conference, Jun. 2006, San Antonio, TX, abstract, 2 pages.Applicant
• Haller et al., “The effects of recombinant human hyaluronidase on drug dispersion,” American Association of Pharmaceutical Scientists Annual Meeting, Nashville, TN, abstract in AAPS Journal 7(S2) May 5, 2005; 3 pages.Applicant
• Haller et al., “Revolutionizing drug dispersion with enhanze technology,” American Association of Pharmaceutical Scientists Annual Meeting, Nov. 6-10, 2005, Nashville, TN, poster, 1 page.Applicant
• Haller et al., “Enhanze technology—A revolution in drug dispersion,” Biotechnology Industry Organization (BIO) Annual Meeting, Jun. 19-22, 2005, Philadelphia, PA, abstract, 3 pages.Applicant
• Haller et al., “Revolutionizing drug dispersion with enhanze technology,” Biotechnology Industry Organization (BIO) Annual Meeting, Jun. 19-22, 2005, Philadelphia, PA, poster, 1 page.Applicant
• Haller, M., “Enhanze technology—An enzymatic drug delivery system (DDS),” Japanese Export Trade Organization, Nov. 2005, Santa Clara, CA, abstract, 3 pages.Applicant
• Haller, M., “Focus on enhanced and innovative recombinant human enzymes,” Japanese Export Trade Organization, Sep. 2004, Chicago, IL, presentation, 16 pages.Applicant
• Haller, M., “Halozyme's enhanze technology for the enhanced dispersion of co-injected pharmaceuticals,” Japanese Export Trade Organization, Sep. 2004, Chicago, IL, abstract, 2 pages.Applicant
• Halozyme Therapeutics, Analyst and Investor Meeting presentations “Matrix Therapeutics for Life” presentations including Lim, J., “Introduction and strategy overview, Roche program update,” Gustafson, K., “Strategic deployment of cash,” Wasserman, R., “HyQ treatment of primary immunodeficiency patients,” Muchmore, D., “Ultrafast insulin—clinical results and ongoing trials,” Cefalu, W., “Unmet needs in diabetes management,” Little, R., Market overview—ultrafast insulin and SC immunoglobin and Frost, G., “PEGPH20 and HT1-501 status report,” Presented Oct. 14, 2010 in New York, NY, 124 pages.Applicant
• Hofer et al., “Human recombinant hyaluronidase increases the convection of molecules up to 0.2 μm in athymic nude mice,” American Association for Laboratory Animal Science, 2006, Salt Lake City, UT. Abstract published in J. Am. Assoc. Lab. Animal Sci., 45:120, abstract P97 (2006), 1 page.Applicant
• Hofer et al., “Human recombinant hyaluronidase increases the convection of molecules up to 0.2 μm in athymic nude mice,” American Association for Laboratory Animal Science, 2006, Salt Lake City, UT, poster P97, 1 page.Applicant
• Halozyme Therapeutics [online], Jefferies 2010 Global Life Science Conference, Published on Jan. 31, 1994 [retrieved on Apr. 29, 2011] [retrieved from the Internet:<URL:wsw.com/webcast/jeff46/hzym/] [7 pages].Applicant
• Halozyme Therapeutics, Jefferies Investor Presentation, “Matrix Therapies for Life,” New York, NY, Jun. 17, 2009, oral presentation [30 pages].Applicant
• Jiang et al., “Effects of recombinant human PH20 (rHuPH20) on interstitial matrices: creating a favorable environment for the delivery of cytostatic agents,” American Association for Cancer Research Annual Meeting 2005, Anaheim, CA, 46:1198, abstract XP001525054, 1 page.Applicant
• Jiang et al., “Reduction of ischemic stroke mortality with chronic intravenous recombinant human hyaluronidase (rHuPH20): effects of pharmacokinetic optimization,” American Neurological Association Annual Meeting, Sep. 25-28, 2005, San Diego, CA, 2 pages.Applicant
• Kang et al., “Use of a recombinant human enzyme for enhanced local adenovirus mediated gene delivery,” American Association of Pharmaceutical Scientists Annual Meeting, Nov. 7-9, 2005, Nashville, TN, poster, 1 page.Applicant
• Kang et al., “Use of a recombinant human enzyme for enhanced local adenovirus mediated gene delivery,” American Association of Pharmaceutical Scientists Annual Meeting, Nov. 7-9, 2005, Nashville, TN, abstract, 1 page.Applicant
• Keller et al., “Pharmacokinetic, pharmacodynamic and toxicologic effects of a recombinant human hyaluronidase (rHuPH20) in rodent and non-human primate models,” Hyaluronan (ISHAS) 2007, Charleston, SC, abstract, 1 page.Applicant
• Keller et al., “Pharmacokinetic, pharmacodynamic and toxicologic effects of a recombinant human hyaluronidase (rHuPH20) in rodent and non-human primate models,” Hyaluronan (ISHAS) 2007, Charleston, SC, poster, 1 page.Applicant
• Kozak et al., “Recombinant human hyaluronidase facilitates dexamethasone penetration into the posterior ocular segment after sub-Tenon's injection,” Association for Research in Vision and Ophthalmology Annual Meeting, May 1-5, 2005, Fort Lauderdale, FL, poster, 1 page.Applicant
• Kozak et al., “Recombinant human hyaluronidase facilitates dexamethasone penetration into the posterior ocular segment after sub-Tenon's injection,” Association for Research in Vision and Ophthalmology Annual Meeting (ARVO) Meeting Abstracts May 1, 2005, 46:478, abstract, 2 pages.Applicant
• Kundu et al., “Dispersion of the cumulus matrix with a highly purified recombinant human hyaluronidase (rHuPH20),” Hyaluronan Meeting, Oct. 11-16, 2003, Cleveland, OH, abstract, 1 page.Applicant
• Kundu et al., “Dispersion of the cumulus matrix with a highly purified recombinant human hyaluronidase (rHuPH20),” Hyaluronan Meeting, Oct. 11-16, 2003, Cleveland, OH, poster, 1 page.Applicant
• Nagy et al., “Prospective, randomized study on bovine and recombinant human (Cumulase®) Hyaluronidases,” American Society of Reproductive Medicine, 2006, New Orleans, LA, 06-A-886-ASRM.Applicant
• Pinkstaff et al., “Evaluation of the compatibility and pharmacokinetics of co-formulated biologics with recombinant human hyaluronidase: dose response,” American Association of Pharmaceutical Scientists Conference, Jun. 2006, San Antonio, TX, poster, 2 pages.Applicant
• Pinkstaff et al., “Evaluation of the compatibility and pharmacokinetics of co-formulated biologics with recombinant human hyaluronidase: dose response,” American Association of Pharmaceutical Scientists Conference, Nov. 2006, abstract, 1 page.Applicant
• Pinkstaff et al., “Recombinant human hyaluronidase for drug and fluid dispersion,” American Association of Pharmaceutical Scientists Annual Meeting, Nov. 2006, Boston, MA, abstract, 1 page.Applicant
• Pinkstaff et al., “Recombinant human hyaluronidase for drug and fluid dispersion,” American Association of Pharmaceutical Scientists Annual Meeting, Nov. 2006, Boston, MA, poster, 2 pages.Applicant
• Wei et al., “Functions of N-linked glycans on human hyaluronidase PH20,” presented at San Diego Glycobiology Symposium 2009. Poster 83, 1 page.Applicant
• Wei et al., “Structure function analysis of the human hyaluronidase enzymes,” American Society for Matrix Biology Biennial Meeting, San Diego, CA, Dec. 5, 2008, poster B4, 1 page.Applicant
• Wilson, M., “Enhanze technology—an enzymatic drug delivery system (DDS),” Japanese Export Trade Organization, Nov. 2005, Santa Clara, CA, oral presentation, 22 pages.Applicant
• Yang et al., “An Alternative Approach for Delivering High Dose Biologics Subcutaneously” presented at PEP TALK, Jan. 11, 2011, oral presentation, 28 pages.Applicant
• International Search Report, issued Aug. 26, 2005, in connection with corresponding International Patent Application No. PCT/US2004/006656, 4 pages.Applicant
• European Search Report, issued Oct. 17, 2006, in connection with corresponding corresponding European Patent Application No. 04717941.1, 8 pages.Applicant
• Office Action, issued Nov. 22, 2006, in connection with corresponding Eurasian Patent Application No. 200501384/26, 2 pages.Applicant
• Examiner's Report, issued Apr. 3, 2007, in connection with corresponding European Patent Application No. 04717941.1, 5 pages.Applicant
• Examination Report, issued Mar. 13, 2008 in connection with corresponding Indian Patent Application No. 4155/DELNP/2005, 1 page.Applicant
• Examination Report, issued Apr. 9, 2008 in connection with corresponding New Zealand Patent Application No. 567053, 5 pages.Applicant
• Office Action, issued Aug. 20, 2008, in connection with U.S. Appl. No. 10/795,095, 23 pages.Applicant
• Examination Report, issued Sep. 29, 2008, in connection with European Patent Application No. 567053, 2 pages.Applicant
• Examination Report, issued Oct. 27, 2008, in connection with Australian Appl. No. 2004218354, 3 pages.Applicant
• Examination Report, issued Dec. 21, 2008, in connection with Israel Application No. 170300, 4 pages.Applicant
• Examination Report, issued Apr. 6, 2009, in connection with Japanese Patent Application No. 2006-509139, 5 pages.Applicant
• Final Office Action, issued Apr. 14, 2009, in connection with U.S. Appl. No. 10/795,095, 15 pages.Applicant
• Office Action, issued Jul. 17, 2009, in connection with Canadian Patent Application No. 200480011489.7, 8 pages.Applicant
• Notice of Intention to Grant, issued Aug. 17, 2009, in connection with European Patent Appl. No. 04717941.1, 4 pages.Applicant
• Office Action, issued Oct. 2, 2009, in connection with Indonesian Patent Application No. W-00200502687, 2 pages.Applicant
• Extended European Search Report, issued Feb. 10, 2010, in connection with European Patent Appl. No. 04717941.1, 7 pages.Applicant
• Extended European Search Report, issued Mar. 10, 2010, in connection with Indonesian Patent Application No. W-00200502687, 9 pages.Applicant
• Response of Sep. 30, 2010 to Written Opinion, issued Mar. 4, 2010, in connection with Singapore Application No. 200706518-8, 21 pages.Applicant
• Written Opinion, issued Mar. 4, 2010, in connection with Singapore Application No. 200706518-8, 16 pages.Applicant
• Examination Report, issued May 10, 2010, in connection with New Zealand Patent Application No. 580202, 2 pages.Applicant
• Examination Report, issued Jul. 20, 2010, in connection with Canadian Patent Application No. 2,517,145, 4 pages.Applicant
• Response of Jan. 20, 2011 to Examination Report, issued Jul. 20, 2010, in connection with corresponding Canadian Application No. 542873, 2 pages.Applicant
• Examination Report, issued Jul. 27, 2010, in connection with New Zealand Patent Application No. 542873, 2 pages.Applicant
• Response of Nov. 11, 2010 to Exam Report, issued Jul. 27, 2010, in connection with corresponding New Zealand Application No. 542873, 31 pages.Applicant
• Notice of Opposition, submitted Aug. 10, 2010, in connection with European Patent No. EP1603541 (Application No. 04717941.1), 32 pages.Applicant
• Commun ication of Notice of Opposition, submitted Aug. 12, 2010, in connection with European Patent No. EP1603541 (Application No. 04717941.1), 1 page.Applicant
• Second Examination Report, issued Dec. 3, 2010, in connection with corresponding New Zealand Application No. 542873, 3 pages.Applicant
• Response of Feb. 1, 2011 toSecond Examination Report, issued Dec. 3, 2010, in connection with corresponding New Zealand Application No. 542873, 29 pages.Applicant
• Second Written Opinion, issued Jan. 21, 2011, in connection with Singapore Application No. 200706518-8, 5 pages.Applicant
• Response of Jul. 8, 2011 to Second Written Opinion, issued Jan. 21, 2011, in connection with Singapore Application No. 200706518-8, 5 pages.Applicant
• Office Action, issued Feb. 17, 2011, in connection with corresponding U.S. Appl. No. 12/378,969, 13 pages.Applicant
• Response of Aug. 17, 2011 to Office Action, issued Feb. 17, 2011, in connection with corresponding U.S. Appl. No. 12/378,969, 16 pages.Applicant
• Examination Report, issued Mar. 2, 2011, in connection with corresponding New Zealand Application No. 542873, 2 pages.Applicant
• Response of Mar. 15, 2011 to Examination Report, issued Mar. 2, 2011, in connection with corresponding New Zealand Application No. 542873, 26 pages.Applicant
• Extended European Search Report, issued Mar. 4, 2011, in connection with corresponding European Application No. 10183285.5, 9 pages.Applicant
• Response of Dec. 8, 2011 to Extended European Search Report, issued Mar. 4, 2011, in connection with corresponding European Application No. 10183285.5, 13 pages.Applicant
• Extended European Search Report, issued Mar. 4, 2011, in connection with corresponding European Application No. 10183319.2, 10 pages.Applicant
• Response to Extended European Search Report, issued Mar. 4, 2011, in connection with corresponding European Application No. 10183319.2, 22 pages.Applicant
• Response of Mar. 24, 2011 to Notice of Opposition, issued Aug. 10, 2010, for corresponding European Patent No. EP 1 603 541, 42 pages.Applicant
• Office Action, issued Mar. 31, 2011, in connection with corresponding South Korean Application No. 10-2005-7016302, 4 pages.Applicant
• Instructions, of Jul. 25, 2011, for response to Office Action, issued Mar. 31, 2011, in connection with corresponding South Korean Application No. 10-2005-7016302, 23 pages.Applicant
• Office Action, issued Apr. 29, 2011, in connection with corresponding U.S. Appl. No. 12/378,984, 24 pages.Applicant
• Response of Oct. 31, 2011 to Office Action, issued Apr. 29, 2011, in connection with corresponding U.S. Appl. No. 12/378,984, 26 pages.Applicant
• Preliminary Opinion and Summons to attend Oral Proceedings, issued Jul. 28, 2011, in connection with European Patent No. 1603541, 6 pages.Applicant
• Office Action, issued Sep. 7, 2011, in connection with U.S. Appl. No. 12/455,657, 12 pages.Applicant
• Examination Report, issued Sep. 13, 2011, in connection with New Zealand Patent Application No. 580202, 2 pages.Applicant
• Office Action, issued Oct. 11, 2011, in connection with U.S. Appl. No. 12/386,273, 12 pages.Applicant
• Office Action, issued Oct. 12, 2011, in connection with U.S. Appl. No. 12/378,969, 5 pages.Applicant
• Response of Nov. 28, 2011, to Office Action, issued Oct. 12, 2011, in connection with U.S. Appl. No. 12/378,969, 8 pages.Applicant
• Office Action, issued Jul. 13, 2011, in connection with Canadian Patent Application No. 2,517,145, received Oct. 31, 2011, 3 pages.Applicant
• Examination Report, issued Nov. 1, 2011, in connection with Australian Patent Application No. 2009245838, 2 pages.Applicant
• European Search Report, issued Nov. 7, 2011, in connection with European Patent Application No. 10183410.9, 9 pages.Applicant
• Office Action, issued Dec. 13, 2011, in connection with Korean Patent Applicaton No. 10-2011-7020286 [English Translation], 4 pages.Applicant
• Notification Prior to Acceptace, issued Dec. 21, 2011, in connection with Israeli Patent Application No. 170300, 4 pages.Applicant
• Final Office Action, issued Dec. 31, 2011, in connection with Chinese Patent Application No. 200480011489.7, 5 pages.Applicant
• Notice of Allowance, issued Jan. 26, 2012, in connection with U.S. Appl. No. 12/378,969, 5 pages.Applicant
• Examination Report, issued Feb. 7, 2012, in connection with European Patent Application No. 09012670.7, 3 pages.Applicant
• Extended European Search Report, issued Feb. 8, 2012, in connection with European Patent Application No. 10183410.9, 15 pages.Applicant
• Office Action, issued Feb. 15, 2012, in connection with U.S. Appl. No. 12/378,984, 25 pages.Applicant
• Ex parte Quayle Action, issued Jun. 26, 2012 in connection with U.S. Appl. No. 12/386,473, 4 pages.Applicant
• Response to Office Action, issued Oct. 11, 2011, in connection with U.S. Appl. No. 12/386,473, 19 pages.Applicant
• Instructions for Request for Re-Examination in response to Final Office Action, issued Dec. 31, 2011, in connection with Chinese Patent Application No. 200480011489.7, 19 pages.Applicant
• Office Action, issued Feb. 14, 2012, in connection with U.S. Appl. No. 12/455,657, 13 pages.Applicant
• Response to Office Action, issued Feb. 14, 2012, in connection with U.S. Appl. No. 12/455,657, 23 pages.Applicant
• Office Action, issued Feb. 16, 2012, in connection with U.S. Appl. No. 12/928,890, 11 pages.Applicant
• Withdrawal of Opposition, mailed Mar. 5, 2012, in connection with European Patent No. 1603541, 1 page.Applicant
• Response to Summons to Attend Oral Proceedings, dated Jul. 28, 2011, in connection with European Patent No. 1603541, including enclosures: Main Request and Auxiliary Request Claims and Annexes A, 1-12, 471 pages.Applicant
• European Patent Office Communication Pursuant to Article 101(1) and Rule 81(2) to (3) EPC, issued Apr. 5, 2012, in connection with Oral Proceedings for European Patent No. 1603541, 3 pages.Applicant
• Notice of Reasons for Rejection, issued Mar. 14, 2012, in connection with Japanese Patent Application No. 2009-184155 [English translation], 5 pages.Applicant
• Examination Report, issued Apr. 3, 2012, in connection with European Patent Application No. 10183319.2, 3 pages.Applicant
• Examination Report, issued Apr. 3, 2012, in connection with European Patent Application No. 10183285.5, 9 pages.Applicant
• Examination Report, issued Apr. 3, 2012, in connection with European Patent Application No. 03012669.9, 3 pages.Applicant
• Communication from the European Patent Office, issued Apr. 20, 2012, in connection with Opposition Proceedings associated with Eurpean Patent No. 1603541, reporting cancellation of the Summons to Attend Oral Proceedings, 1 page.Applicant
• Decision of Reexamination, issued Apr. 24, 2012, in connection with Chinese Patent Application No. 200480011489.7 [English translation], 1 page.Applicant
• Interlocutory Decision in Opposition Proceedings, issued May 15, 2012 in connection with European Patent No. 1603541, 6 pages.Applicant
• Final Office Action, issued May 24, 2012 in connection with U.S. Appl. No. 12/386,473, 18 pages.Applicant
• Response to final Office Action, issued May 24, 2012 in connection with U.S. Appl. No. 12/386,473, 8 pages.Applicant
• Office Action, issued Jun. 11, 2012 in connection with U.S. Appl. No. 12/455,657, 14 pages.Applicant
• Letter/Written Disclosure of the Information Disclosure Statement for the above-referenced application, mailed on Feb. 14, 2013, 2 pages.Applicant
• Frost, G. I., “Halozyme Therapeutics, Inc. Thinking outside the cell,” presented at J. P. Morgan Healthcare Conference on Jan. 10, 2013. Presentation. 23 pages.Applicant
• Halozyme Therapeutics Investor Presentation, “Company Overview,” Feb. 1, 2006, 34 pages.Applicant
• Halozyme Therapeutics Investor Presentation, “Company Overview,” Feb. 12, 2008, 37 pages.Applicant
• Halozyme Therapeutics Investor Presentation, “Company Overview,” Feb. 22, 2007, 25 pages.Applicant
• Halozyme Therapeutics Investor Presentation, “Company Overview,” Jun. 28, 2006, 28 pages.Applicant
• Halozyme Therapeutics Investor Presentation, “Company Overview,” May 15, 2008, 15 pages.Applicant
• Halozyme Therapeutics Investor Presentation, “Company Overview,” Nov. 29, 2005, 34 pages.Applicant
• Halozyme Therapeutics Investor Presentation, “Focus on enhanced and innovative recombinant human enzymes,” Jan. 28, 2005, 28 pages.Applicant
• News Release, “Halozyme Therapeutics And Pfizer enter into a collaboration to develop and commercialize subcutaneous biologics using recombinant human hyaluronidase,” Published on Dec. 21, 2012 [online] [Retrieved on Jan. 3, 2013] Retrieved from:<URL:halozyme.com/Investors/News-Releases/News-Release-Details/2012/Halozyme-Therapeutics-And-Pfizer-Enter-Into-A-Collaboration-To-Develop-And-Commercialize-Subcutaneous-Biologics-Using-Recombi/default.aspx, 2 pages.Applicant
• News Release, “ViroPharma and Halozyme Therapeutics announce initiation of phase 2b dose ranging combination study for subcutaneous administration of Cinryze® (C1 esterase inhibitor [human]) with hyaluronidase (rHuPH20),” Published on Dec. 19, 2012 [online][ Retrieved on Jan. 3, 2013] Retrieved from:<URL:halozyme.com/Investors/News-Releases/News-Release-Details/2012/ViroPharma-and-Halozyme-Therapeutics-Announce-Initiation-of-Phase-2b-Dose/default.aspx, 4 pages.Applicant
• News Release, “Halozyme Therapeutics to present at the 31st Annual J.P. Morgan Healthcare Conference,” Published Jan. 3, 2013 [online][Retrieved Jan. 17, 2013][ Retrieved from:<URL:halozyme.com/Investors/News-Releases/News-Release-Details/2013/Halozyme-Therapeutics-to-Present-at-the-31st-Annual-JP-Morgan-Healthcare-Conference1132508/default.aspx, 2 pages.Applicant
• Response to Office Actio n, issued Jul. 13, 2011, in connection with Canadian Pate nt Application No. 2,517,145, 62 pages.Applicant
• Response to Extended European Search Report, issued Feb. 8, 2012, in connection with European Patent Application No. 10183410.9, 29 pages.Applicant
• Response to Notice of Reasons for Rejection, issued Mar. 14, 2012, in connection with Japanese Patent Application No. 2009-184155, 22 pages.Applicant
• Instructions for response to Office Action, issued Dec. 13, 2011, in connection with Korean Patent Application No. 10-2011-7020286, 19 pages.Applicant
• Office Action, issued Jul. 17, 2012 in connection with Chinese Patent Application No. 200480011489.7 [English translation], 3 pages.Applicant
• Response to Office Action, issued Feb. 15, 2012, in connection with U.S. Appl. No. 12/378,984, 36 pages.Applicant
• Response to Office Action, issued Feb. 16, 2012, in connection with U.S. Appl. No. 12/928,890, 39 pages.Applicant
• Response to Ex parte Quayle Action, mailed Jun. 26, 2012 in connection with U.S. Appl. No. 12/386,473, 6 pages.Applicant
• Response to Examination Report, issued Apr. 3, 2012, in connection with European Patent Application No. 03012669.9, 10 pages.Applicant
• Response to Examination Report, issued Apr. 3, 2012, in connection with European Patent Application No. 10183285.5, 5 pages.Applicant
• Response to Examination Report, issued Apr. 3, 2012, in connection with European Patent Application No. 10183319.2, 13 pages.Applicant
• Response to Examination Report, issued Feb. 7, 2012, in connection with European Patent Application No. 09012670.7, 20 pages.Applicant
• Response to Office Action, issued Jun. 11, 2012 in connection with U.S. Appl. No. 12/455,657, 10 pages.Applicant
• Instructions for Response to Office Action, issued Jul. 17, 2012 in connection with Chinese Patent Application No. 200480011489.7, 17 pages.Applicant
• Office Action, issued Aug. 31, 2012, in connection with Korean Patent Application No. 10/2012-7015300 [English translation], 13 pages.Applicant
• Notice of Allowance, mailed Sep. 27, 2012, in connection with U.S. Appl. No. 12/386,473, 6 pages.Applicant
• Final Office Action, issued Sep. 25, 2012, in connection with U.S. Appl. No. 12/378,984, 15 pages.Applicant
• Amendment After Final in response to Final Office Action, issued Sep. 25, 2012, in connection with U.S. Appl. No. 12/378,984, 12 pages.Applicant
• Final Office Action, Oct. 9, 2012, in connection with U.S. Appl. No. 12/455,657, 10 pages.Applicant
• Amendment After Final, in response to final Office Action, Oct. 9, 2012, in connection with U.S. Appl. No. 12/455,657, 8 pages.Applicant
• Notice of Allowability, mailed Nov. 27, 2012, in connection with U.S. Appl. No. 12/455,657, 6 pages.Applicant
• Final Office Action, mailed Nov. 28, 2012, in connection with U.S. Appl. No. 12/928,890, 14 pages.Applicant
• Response to final Office Action, mailed Nov. 28, 2012, in connection with U.S. Appl. No. 12/928,890, 15 pages.Applicant
• Notice of Allowance, issued Dec. 12, 2012, in connection with Korean Patent Application No. 10-2011-7020286, 2 pages.Applicant
• Notice of Allowance, mailed Jan. 8, 2013, in connection with U.S. Appl. No. 12/378,984, 4 pages.Applicant
• Letter/Written Disclosure of the Supplemental Information Disclosure Statement for the above-referenced application, mailed on Apr. 11, 2013, 2 pages.Applicant
• Response to Examination Report, issued Nov. 1, 2011, in connection with Australian Patent Application No. 2009245838, 15 pages.Applicant
• Instructions for response to Office Action, issued Aug. 31, 2012, in connection with Korean Patent Application No. 10/2012-7015300, 23 pages.Applicant
• Examination Report, issued Feb. 6, 2013, in connection with European Patent Application No. 09012669.9, 3 pages.Applicant
• Examination Report, issued Feb. 6, 2013, in connection with European Patent Application No. 10183410.9, 3 pages.Applicant
• Notice of Allowance, mailed Feb. 21, 2013, in connection with Chinese Patent Application No. 200480011489.7 [English language translation], 8 pages.Applicant
• Leter/Written Disclosure of the Supplemental Information Disclosure Statement for the above-referenced application, mailed the same day herewith, 2 pages.Applicant
• Notice of Acceptance, issued Apr. 15, 2013, in connection with Australian Patent Application No. 2009245838, 2 pages.Applicant
• Examination Report, issued Jun. 26, 2013, in connection with European Patent Application No. 10183285.5, 4 pages.Applicant
• Examination Report, issued Jul. 3, 2013, in connection with European Patent Application No. 10183319.2, 3 pages.Applicant
• Advisory Action, mailed Mar. 5, 2013, in connection with U.S. Appl. No. 12/928,890, 2 pages.Applicant
• Second Amendment After Final, dated Apr. 26, 2013, in response to final Office Action, mailed Nov. 28, 2012, in connection with U.S. Appl. No. 12/928,890, 9 pages.Applicant
• Advisory Action, mailed May 1, 2013, in connection with U.S. Appl. No. 12/928,890, 3 pages.Applicant
• Final Rejection, issued Jul. 29, 2013, in connection with Korean Patent Application No. 10/2012-7015300 [English translation], 4 pages.Applicant
• Letter/Written Disclosure of the Supplemental Information Disclosure Statement for the above-referenced application, mailed Oct. 18, 2013, 2 pages.Applicant
• Examination Report, issued Sep. 6, 2013, in connection with Australian Patent Application No. 2013202475, 2 pages.Applicant
• Office Action, issued Aug. 30, 2013, in connection with Chinese Patent Application No. 201210442499.2 [English language translation], 8 pages.Applicant
• Response, dated Sep. 11, 2013, to Examination Report, issued Jul. 3, 2013, in connection with European Patent Application No. 10183319.2, 8 pages.Applicant
• Response to Examination Report, issued Feb. 6, 2013, in connection with European Patent Application No. 10183410.9, 25 pages.Applicant
• Supplemental Response, dated Sep. 13, 2013, to Examination Report, issued Feb. 6, 2013, in connection with European Patent Application No. 10183410.9, 10 pages.Applicant
• Office Action, mailed Sep. 13, 2013, in connection with U.S. Appl. No. 13/694,005, 15 pages.Applicant
• Letter/Written Disclosure of the Supplemental Information Disclosure Statement for the above-referenced application, mailed Feb. 21, 2014, 2 pages.Applicant
• Harooni et al., “Efficacy of hyaluronidase in reducing increases in intraocular pressure related to the use of viscoelastic substances,” Arch Ophthalmol; 116(9):1218-1221 (1998).Applicant
• Johnsson et al., “Hyaluronidase can be used to reduce interstitial edema in the presence of heparin,” Journal of Cardiovascular Pharmacology and Therapeutics 5(3):229-236 (2000).Applicant
• Kerbel et al., “Induction and reversal of cell adhesion-dependent multicellular drug resistance in solid breast tumors,” Hum Cell; 9(4):257-264 (1996).Applicant
• Woodward et al., “Peribulbar anaesthesia with 1% ropivacaine and hyaluronidase 300 IU ml-1: comparison with 0.5% bupivacaine/2% lidocaine and hyaluronidase 50 IU ml-1,” Br J Anaesth; 85(4):618-620 (2000).Applicant
• Notification of Intention to Grant corresponding European Patent Application No. 10183410.9, dated Dec. 9, 2013, 7 pages.Applicant
• Search Report and Written Opinion, issued Jan. 21, 2014, in connection with corresponding Singapore Patent Application No. 201204106-7, 17 pages.Applicant